AlcoholismPhase 2NCT00498628
Study of the Effectiveness of Quetiapine for the Treatment of Alcohol Dependency
A Phase 2 study testing Quetiapine fumarate in people with Alcoholism and Alcohol Abuse, run by National Institute on Alcohol Abuse and Alcoholism (NIAAA) at 7 sites in United States.
Trial summary
The purpose of this study is to determine whether quetiapine fumarate extended release is effective in the treatment of alcohol dependence in very heavy drinkers. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Alcoholism, Alcohol Abuse
- What is being tested?
- Quetiapine fumarate
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 224 participants
- Where
- 7 sitesUnited States
- Study dates
- Dec 2007to Mar 2010
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Between the ages of 18 and 65 years old
- DSM-IV diagnosis of current alcohol dependence as supported by SCID Module E
- Report "very heavy" drinking (10 or more drinks per drinking day for men or 8 or more drinks per drinking day for women) at least 40% of the days during the interval from day 31 to 90 prior to the initial screening visit (i.e. a total of 24 days of this 60-day period), with at least one day of "very heavy" drinking occurring within the last 2 weeks before screening
- Seeking treatment for alcohol dependence and desire reduction or cessation of drinking
- Able to verbalize understanding of the consent form, able to provide written informed consent, and verbalize willingness to complete study procedures
- Females of child bearing potential must agree to use of at least one approved method of birth control, or must be surgically sterile or postmenopausal
Show all 12Show fewer
- Able to take oral medication, willing to adhere to the medication regimen, and willing to return for regular visits
- Able to understand written and oral instructions in English and to complete the questionnaires required by the protocol
- Can complete all psychological assessments required at screening and baseline
- Able to provide evidence of stable residence in the last 2 months prior to randomization, have reasonable transportation arrangements to study site, and have no plans to move within the next 3 months or unresolved legal problems; must provide contact information of family member, spouse, or significant other who can contact subject in case of missed appointment
- Breath alcohol concentration (BAC) equal to 0.00 when s/he signed the informed consent document
- Must have an absolute neutrophil count of 1.5 x 109/L or greater.
Who cannot join
- Please contact site for additional information.
Trial locations and contacts
7 sites in 1 country.
7 sites in 1 country
United States7 sites
Boston University School of Medicine, Psychiatry Clinical Studies Unit
Boston, Massachusetts, 02118
University of Virginia, Dept. of Psychiatric Medicine
Charlottesville, Virginia, 22908
Dartmouth Medical School, Dept. of Psychiatry
Lebanon, New Hampshire, 03755
University of Pennsylvania, Treatment Research Center
Philadelphia, Pennsylvania, 19104
Brown University Center for Alcohol and Addiction Studies
Providence, Rhode Island, 12906
University of Virginia
Richmond, Virginia, 23294
White River Junction VA Medical Center
White River Junction, Vermont, 05009
About this study
Official title: A Phase 2, Double-Blind, Placebo Controlled Trial to Assess the Efficacy of Quetiapine Fumarate Extended Release for the Treatment of Alcohol Dependence in Very Heavy Drinkers.
The purpose of this study is to determine whether quetiapine fumarate extended release is effective in the treatment of alcohol dependence in very heavy drinkers.
Read the detailed description
This study will investigate quetiapine fumarate XR (SEROQUEL XR®), a dibenzothiazepine derivative, as a potential medication for treating alcohol dependence. The immediate release form of quetiapine fumarate, SEROQUEL XR®, is approved by the FDA for treatment of schizophrenia and acute manic episodes associated with bipolar disorder. The extended release formulation (SEROQUEL XR®) is also approved by the FDA and is undergoing clinical investigation for the treatment of major depressive disorders, schizophrenia, generalized anxiety disorder, and alcohol dependence.
Treatment with other atypical antipsychotics such as clozapine and olanzapine has resulted in decreases in alcohol use in alcohol dependent patients with and without comorbid psychiatric diagnoses. Quetiapine, like clozapine, appears to have efficacy in reducing drug and alcohol use among alcoholics and drug dependent patients with co-morbid psychiatric illness.
- Conditions
- Alcoholism, Alcohol Abuse
- Being tested
- Quetiapine fumarate, Placebo
- Keywords
- Alcoholism, Alcohol dependence, Quetiapine
- Medical subject headings
- Alcoholism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Quetiapine fumarateDrug
Also called SEROQUEL XR
Quetiapine fumarate- taken daily, for 12 weeks
PlaceboOther
Placebo
| Study group | Role | What they receive |
|---|---|---|
| 1 | Experimental | Quetiapine fumarate plus medical management Receives: Drug: Quetiapine fumarate |
| 2 | Placebo comparator | Medical management plus placebo comparator Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percent Heavy Drinking Days
A heavy drinking day is defined as 5 or more drinks for men and 4 or more drinks for women during a 24 hour period.
Measured: Weeks 3 - 11
Secondary outcomes (13)
Percent Days Abstinent
Timeline Follow-back drinking data is used to calculate the % of days abstinent per week during Weeks 3-11
Measured: Weeks 3-11
Drinks Per Drinking Day
Timeline Follow Back daily drinking data used to calculate the weekly mean drinks per drinking day
Measured: Study Weeks 3-11
Drinks Per Day
Timeline Follow Back daily drinking data used to calculate the weekly mean drinks per day
Measured: Study Weeks 3-11
Percent Very Heavy Drinking Day
Timeline Follow Back data used to calculate the % of very heavy drinking days per week. Heavy drinking is 10+ drinks per day for females and 12+ drinks per day for males
Measured: Study Weeks 3-11
Percent Subjects Abstinent
Timeline Follow Back data used to calculate the % of subjects that maintained abstinence weeks 3-11.
Measured: Study Weeks 3-11
Percent Subjects With no Heavy Drinking Day
Timeline Follow Back data used to calculate the % of subjects that didn't have a heavy drinking day during study weeks 3-11.
Measured: Study Weeks 3-11
Drinking Consequences Score
Drinkers Inventory of Consequences (DrInC) - Alcohol-related problems are determined using the DrInC (Miller et al., 1995). The DrInC is a self-administered 50-item questionnaire designed to measure adverse consequences of alcohol abuse in five areas: Interpersonal, Physical, Social, Impulsive, and Intrapersonal. Each scale provides a lifetime and past 3-month measure of adverse consequences, and scales can be combined to assess total adverse consequences. We used a modified version of the DrInC that just included the 45-items that summed the Interpersonal, Physical, Social, and Impulsivity items. This total score (min=0, max=135) was analyzed in this study with high scores indicative of more alcohol-related consequences (a poor outcome for a given study participant). The DrInC was assessed at study weeks 6 and 12. Analyses averaged across these weeks.
Measured: Weeks 6 & 12
Penn Alcohol Craving Score (PACS_
The Penn Alcohol Craving Scale (PACS) is a five-item, self-report measure that includes questions about the frequency, intensity, and duration of craving, the ability to resist drinking, and asks for an overall rating of craving for alcohol for the previous week (Flannery et al., 1999). The summed total score of the 5 items was used in the analysis (min=0, max=30) with higher scores indicative of higher craving for alcohol (a poor outcome). Based on clinical study results, the PACS has been shown to be a reliable and valid measure of alcohol craving and can predict subjects at risk for subsequent relapse. The PACS was assessed at study weeks 4, 6, 8, 10, and 12. Analyses averaged across these weeks.
Measured: Weeks 4, 6, 8, 10, and 12
Montgomery-Asberg Depression Rating Scale (MADRS)
The MADRS is an observer rating scale that has proven to be an efficient and practical measure of depression (Montgomery and Asberg, 1979). The scale was constructed to be sensitive to changes in treatment effects. Its capacity to differentiate between responders and non-responders to antidepressant treatment has been shown to be comparable to the Hamilton Rating Scale for Depression, another established measure of depressive symptomatology, but the MADRS has greater sensitivity to change during the course of a depressive phase. It has exhibited high inter-rater reliability and appears to be oriented more towards psychic as opposed to somatic aspects of depression. The MADRS is the sum of the 10-item in a checklist where items are rated on a scale of 0 to 6 with anchors at 2-point intervals. Scores range from 0 to 60. Higher scores are indicative of greater depressive symptoms (a poor outcome). The MADRS was assessed at weeks 4, 6, 8, 10, and 12. Analyses averaged across these weeks.
Measured: Weeks 3-11
Hamilton Anxiety Scale (HAM-A)
The Hamilton Anxiety Scale consists of 14 items, each defined by a series of symptoms. Similar to the HAM-D, each item is rated on a 5-point scale, ranging from 0 (not present) to 4 (severe) (Guy, 1976). A total score is derived from the summed items (min=0, max=56) with higher scores indicative of greater anxiety (a poor outcome). The HAM-A was assessed at study weeks 4, 6, 8, 10, and 12. Analyses averaged across these weeks.
Measured: Weeks 4, 6, 8, 10, and 12
Pittsburgh Sleep Quality Score
The PSQI is a 19-item questionnaire assessing the subject's overall sleep experience in the past 30 days (Buysse et al-1989). The lower the overall score, the better the person sleeps. The tool has an adequate internal reliability, validity and consistency for clinical and community samples of the various populations. Range is (0-21); >6 indicative of "poor" sleep quality. The PSQI was assessed at study weeks 4,8, and 12. Analyses averaged across these weeks.
Measured: Weeks 4, 8, 12
Quality of Life SF - 12 - Mental Aggregate Score
The SF-12 will be used to assess overall health status. The SF-12 is a 12-item questionnaire developed in 1994 as a shorter alternative to the SF-36 to reproduce the physical and mental health summary measures with at least 90% accuracy. We calculated the physical and mental component summary scores which were both converted to T-scores (min=0, max=100) normed to the general population such that a T=50 is the average score in the general population. Higher scores are indicative of better health status.
Measured: Week 12
Quality of Life SF-12 - Physical Aggregate Score
The SF-12 will be used to assess overall health status. The SF-12 is a 12-item questionnaire developed in 1994 as a shorter alternative to the SF-36 to reproduce the physical and mental health summary measures with at least 90% accuracy. We calculated the physical and mental component summary scores which were both converted to T-scores (min=0, max=100) normed to the general population such that a T=50 is the average score in the general population. Higher scores are indicative of better health status.
Measured: Week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jul 2007 (estimated)
- Study startDec 2007
- Primary completionAug 2009
- Study completionMar 2010
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for AlcoholismStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 224 participants (actual)
Sponsor and investigators
- Lead sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- Sponsor type
- US National Institutes of Health
- Collaborators
- National Institute on Drug Abuse (NIDA), AstraZeneca, US Department of Veterans Affairs
- Responsible party
- Sponsor
- Investigators
- Raye Z. Litten, PhD, Study director, National Institute on Alcohol Abuse and Alcoholism (NIAAA)Margaret E. Mattson, PhD, Principal investigator, National Institute on Alcohol Abuse and Alcoholism (NIAAA)Joanne Fertig, PhD, Principal investigator, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00498628
- Sponsor's protocol ID
- NIAAA_DTRR-2007-LITTEN-01
- Status last verified
- Feb 2019
- First submitted
- 6 Jul 2007
- Last updated
- 19 Mar 2019
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Litten RZ, Fertig JB, Falk DE, Ryan ML, Mattson ME, Collins JF, Murtaugh C, Ciraulo D, Green AI, Johnson B, Pettinati H, Swift R, Afshar M, Brunette MF, Tiouririne NA, Kampman K, Stout R; NCIG 001 Study Group. A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients. Alcohol Clin Exp Res. 2012 Mar;36(3):406-16. doi: 10.1111/j.1530-0277.2011.01649.x. Epub 2011 Sep 26.
PubMed 21950727Vatsalya V, Kong M, Marsano LM, Kurlawala Z, Chandras KV, Schwandt ML, Ramchandani VA, McClain CJ. Interaction of Heavy Drinking Patterns and Depression Severity Predicts Efficacy of Quetiapine Fumarate XR in Lowering Alcohol Intake in Alcohol Use Disorder Patients. Subst Abuse. 2020 Sep 9;14:1178221820955185. doi: 10.1177/1178221820955185. eCollection 2020.
PubMed 32963470
Study at a glance
From the registry record, last updated by the sponsor on 19 Mar 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 2, Double-Blind, Placebo Controlled Trial to Assess the Efficacy of Quetiapine Fumarate Extended Release for the Treatment of Alcohol Dependence in Very Heavy Drinkers.
- ClinicalTrials.gov ID
- NCT00498628
- Acronym / sponsor ID
- NIAAA_DTRR-2007-LITTEN-01
- Conditions
- Alcoholism, Alcohol Abuse
- Keywords
- Alcoholism, Alcohol dependence, Quetiapine
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 224 participants (actual)
- Lead sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)US National Institutes of Health
- Collaborators
- National Institute on Drug Abuse (NIDA), AstraZeneca, US Department of Veterans Affairs
- Study start
- Dec 2007
- Primary completion
- Aug 2009 (actual)
- Study completion
- Mar 2010 (actual)
- First posted
- 10 Jul 2007 (estimated)
- Results
- Posted 30 May 2012
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine whether quetiapine fumarate extended release is effective in the treatment of alcohol dependence in very heavy drinkers.
Detailed description
This study will investigate quetiapine fumarate XR (SEROQUEL XR®), a dibenzothiazepine derivative, as a potential medication for treating alcohol dependence. The immediate release form of quetiapine fumarate, SEROQUEL XR®, is approved by the FDA for treatment of schizophrenia and acute manic episodes associated with bipolar disorder. The extended release formulation (SEROQUEL XR®) is also approved by the FDA and is undergoing clinical investigation for the treatment of major depressive disorders, schizophrenia, generalized anxiety disorder, and alcohol dependence.
Treatment with other atypical antipsychotics such as clozapine and olanzapine has resulted in decreases in alcohol use in alcohol dependent patients with and without comorbid psychiatric diagnoses. Quetiapine, like clozapine, appears to have efficacy in reducing drug and alcohol use among alcoholics and drug dependent patients with co-morbid psychiatric illness.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 1 | Experimental | Drug: Quetiapine fumarateQuetiapine fumarate plus medical management |
| 2 | Placebo comparator | Other: PlaceboMedical management plus placebo comparator |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (12 listed)
- Between the ages of 18 and 65 years old
- DSM-IV diagnosis of current alcohol dependence as supported by SCID Module E
- Report "very heavy" drinking (10 or more drinks per drinking day for men or 8 or more drinks per drinking day for women) at least 40% of the days during the interval from day 31 to 90 prior to the initial screening visit (i.e. a total of 24 days of this 60-day period), with at least one day of "very heavy" drinking occurring within the last 2 weeks before screening
- Seeking treatment for alcohol dependence and desire reduction or cessation of drinking
- Able to verbalize understanding of the consent form, able to provide written informed consent, and verbalize willingness to complete study procedures
Key exclusion criteria (1 listed)
- Please contact site for additional information.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Quetiapine fumarateAlso: SEROQUEL XRQuetiapine fumarate- taken daily, for 12 weeks | Drug | 1 |
| PlaceboPlacebo | Other | 2 |
Primary outcome
Percent Heavy Drinking Days
Time frame: Weeks 3 - 11
A heavy drinking day is defined as 5 or more drinks for men and 4 or more drinks for women during a 24 hour period.
13 secondary outcomes
Percent Days Abstinent
Time frame: Weeks 3-11
Drinks Per Drinking Day
Time frame: Study Weeks 3-11
Drinks Per Day
Time frame: Study Weeks 3-11
Percent Very Heavy Drinking Day
Time frame: Study Weeks 3-11
Percent Subjects Abstinent
Time frame: Study Weeks 3-11
Percent Subjects With no Heavy Drinking Day
Time frame: Study Weeks 3-11
Drinking Consequences Score
Time frame: Weeks 6 & 12
Penn Alcohol Craving Score (PACS_
Time frame: Weeks 4, 6, 8, 10, and 12
Montgomery-Asberg Depression Rating Scale (MADRS)
Time frame: Weeks 3-11
Hamilton Anxiety Scale (HAM-A)
Time frame: Weeks 4, 6, 8, 10, and 12
Pittsburgh Sleep Quality Score
Time frame: Weeks 4, 8, 12
Quality of Life SF - 12 - Mental Aggregate Score
Time frame: Week 12
Quality of Life SF-12 - Physical Aggregate Score
Time frame: Week 12
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Mar 2019.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Results publication: PubMed 21950727Litten RZ, Fertig JB, Falk DE, Ryan ML, Mattson ME, Collins JF, Murtaugh C, Ciraulo D, Green AI, Johnson B, Pettinati H, Swift R, Afshar M, Brunette MF, Tiouririne NA, Kampman K, Stout R; NCIG 001 Study Group. A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients. Alcohol Clin Exp Res. 2012 Mar;36(3):406-16. doi: 10.1111/j.1530-0277.2011.01649.x. Epub 2011 Sep 26.
- Derived from this study: PubMed 32963470Vatsalya V, Kong M, Marsano LM, Kurlawala Z, Chandras KV, Schwandt ML, Ramchandani VA, McClain CJ. Interaction of Heavy Drinking Patterns and Depression Severity Predicts Efficacy of Quetiapine Fumarate XR in Lowering Alcohol Intake in Alcohol Use Disorder Patients. Subst Abuse. 2020 Sep 9;14:1178221820955185. doi: 10.1177/1178221820955185. eCollection 2020.
Related trials for Alcoholism
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
RecruitingPhase 1
Environment and Alcohol: A Pilot Study
Alcohol Use Disorder
RecruitingObservational study
SMART-r: Substance Monitoring and Active Relapse Tracking Repository
Alcoholism, Substance-Related Disorders
Not yet recruiting
A MRT to Optimize a JITAI for Alcohol Craving and Suicide Ideation
Alcohol Use Disorder (AUD), Suicide Ideation
RecruitingPhase 2
Study on Thiamine Supplementation to REduce braiN Injury Associated With Chronic Alcohol Use in Outpatients With Alcohol Use Disorder
Alcohol Use Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Raye Z. Litten, PhD study director
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Margaret E. Mattson, PhD principal investigator
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Joanne Fertig, PhD principal investigator
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
7 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Quetiapine fumarate in people with Alcoholism and Alcohol Abuse, run by National Institute on Alcohol Abuse and Alcoholism (NIAAA) at 7 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Mar 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 7 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 30 May 2012). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percent Heavy Drinking Days (time frame: Weeks 3 - 11). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00498628, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Mar 2019; AzTrials last refreshed its copy on 8 Nov 2026.